1-10 of 10
Stephen W. Erickson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium

Pooja Hingorani, Wendong Zhang, Zhongting Zhang, Zhaohui Xu, Wei-Lien Wang, Michael E. Roth, Yifei Wang, Jonathan B. Gill, Douglas J. Harrison, Beverly A. Teicher, Stephen W. Erickson, Gregory Gatto, Edward A. Kolb, Malcolm A. Smith, Raushan T. Kurmasheva, Peter J. Houghton, Richard Gorlick
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (8): 1318–1325.
https://doi.org/10.1158/1535-7163.MCT-21-0758
Published: 02 August 2022
View article titled, Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium
Open the PDF for Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium in another window
Journal Articles

Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma

Yifei Wang, Xiangjun Tian, Wendong Zhang, Zhongting Zhang, Rossana Lazcano, Pooja Hingorani, Michael E. Roth, Jonathan D. Gill, Douglas J. Harrison, Zhaohui Xu, Sylvester Jusu, Sankaranarayanan Kannan, Jing Wang, Alexander J. Lazar, Eric J. Earley, Stephen W. Erickson, Tara Gelb, Philip Huxley, Johanna Lahdenranta, Gemma Mudd, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith, Edward A. Kolb, Richard Gorlick
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (6): 903–913.
https://doi.org/10.1158/1535-7163.MCT-21-0836
Published: 01 June 2022
View article titled, Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
Open the PDF for Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma in another window
Includes: Supplementary data
Journal Articles

Abstract LB-B04: A multi-omic surfaceome study identifies DLK1 as an epigenetically regulated protein and immunotherapeutic target in neuroblastoma

Amber K. Weiner, Alexander B. Radaoui, Matthew Tsang, Dan Martinez, Simone Sidoli, Karina L. Conkrite, Alberto Delaidelli, Jo Lynne Rokita, Maria V. Lane, Zalman Vaksman, Komal S. Rathi, Pichai Raman, Jennifer Pogoriler, Tricia Bhatti, Bruce Pawel, Beverly Teicher, Stephen W. Erickson, Poul Sorensen, Yael P. Mosse, Kateryna Krytska, Francesca Zammarchi, Patrick H. van Berkel, Malcolm A. Smith, Benjamin A. Garcia, John M. Maris, Sharon J. Diskin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): LB-B04.
https://doi.org/10.1158/1535-7163.TARG-19-LB-B04
Published: 01 December 2019
View article titled, Abstract LB-B04: A multi-omic surfaceome study identifies DLK1 as an epigenetically regulated protein and immunotherapeutic target in neuroblastoma
Journal Articles

Abstract C003: Initial testing of m276-PBD CD276 antibody-drug conjugate in preclinical models of pediatric cancers by the Pediatric Preclinical Testing Consortium (PPTC)

Raushan Kurmasheva, E. Anders Kolb, Malcolm A. Smith, Beverly A. Teicher, Stephen W. Erickson, John M. Maris, Yael P. Mosse, Kateryna Krytska, David Groff, Matthew Tang, Yifei Wang, Brad St. Croix, Richard Gorlick, Peter J. Houghton
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C003.
https://doi.org/10.1158/1535-7163.TARG-19-C003
Published: 01 December 2019
View article titled, Abstract C003: Initial testing of m276-PBD CD276 antibody-drug conjugate in preclinical models of pediatric cancers by the Pediatric Preclinical Testing Consortium (PPTC)
Journal Articles

Abstract C004: The CXCR4 inhibitor X4-136 enhances the in vivo efficacy of established drugs against preclinical models of aggressive pediatric acute lymphoblastic leukemia

Richard B Lock, Kathryn Evans, Connor D Jones, Narimanne El-Zein, Stephen W Erickson, Sarah Beaussant-Cohen, E. Lynne Kelley, Beverly A Teicher, Malcolm A Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C004.
https://doi.org/10.1158/1535-7163.TARG-19-C004
Published: 01 December 2019
View article titled, Abstract C004: The CXCR4 inhibitor X4-136 enhances the <em>in vivo</em> efficacy of established drugs against preclinical models of aggressive pediatric acute lymphoblastic leukemia
Journal Articles

Abstract LB-B16: The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study

Richard B. Lock, Kathryn Evans, Raymond Yung, Tara Pritchard, Beverly A. Teicher, JianXin Duan, Yuelong Guo, Stephen W. Erickson, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B16.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B16
Published: 01 January 2018
View article titled, Abstract LB-B16: The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound <em>In Vivo</em> Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study
Journal Articles

Abstract LB-B15: Pediatric Preclinical Testing Consortium evaluation of the AZD1775 as a single agent and in combination with irinotecan

Peter J. Houghton, Raushan T. Kurmasheva, Richard Gorlick, E. Anders Kolb, Yael P. Mosse, Stephen W. Erickson, Yuelong Guo, Beverly A. Teicher, Malcolm A. Smith, John M. Maris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B15.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B15
Published: 01 January 2018
View article titled, Abstract LB-B15: Pediatric Preclinical Testing Consortium evaluation of the AZD1775 as a single agent and in combination with irinotecan
Journal Articles

Abstract LB-B12: Pediatric Preclinical Testing Consortium evaluation of 4’-thio-2’-deoxycytidine (TdCyd) and 5-aza-4’-thio-2’-deoxycytidine (Aza-TdCyd)

Beverly A. Teicher, Richard B. Lock, Jerry M. Collins, Richard Gorlick, E. Anders Kolb, Peter J. Houghton, Raushan T. Kurmasheva, Xiao-Nan Li, Stephen W. Erickson, Yuelong Guo, Kathryn Evans, Lin Qi, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B12.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B12
Published: 01 January 2018
View article titled, Abstract LB-B12: Pediatric Preclinical Testing Consortium evaluation of 4’-thio-2’-deoxycytidine (TdCyd) and 5-aza-4’-thio-2’-deoxycytidine (Aza-TdCyd)
Journal Articles

Abstract LB-B14: Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602

Kateryna Krytska, Kathryn Evans, Tara Pritchard, Matthew Tsang, Raymond Yung, Yael P. Mosse, Stephen W. Erickson, Yuelong Guo, Erkan Baloglu, Yosef Landesman, Kyle A. Jensen, William Senapedis, Beverly A. Teicher, Malcolm A. Smith, Richard B. Lock, John M. Maris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B14.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B14
Published: 01 January 2018
View article titled, Abstract LB-B14: Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602
Journal Articles

Abstract LB-B13: Pediatric Preclinical Testing Consortium evaluation of the CHK1 inhibitor prexasertib

Kristina A. Cole, Peter J. Houghton, Raushan T. Kurmasheva, Richard Gorlick, E. Anders Kolb, Min Kang, C. Patrick Reynolds, Xiao-Nan Li, Holly Lindsay, Stephen W. Erickson, Yuelong Guo, Beverly A. Teicher, Malcolm A. Smith, John M. Maris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B13.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B13
Published: 01 January 2018
View article titled, Abstract LB-B13: Pediatric Preclinical Testing Consortium evaluation of the CHK1 inhibitor prexasertib